Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO’21 Virtual Congress
28 mai 2021 08h00 HE
|
Morphic Therapeutic
Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens...
Morphic Therapeutic to Present at the Jefferies Virtual Healthcare Conference
28 mai 2021 07h30 HE
|
Morphic Therapeutic
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results
29 avr. 2021 08h00 HE
|
Morphic Therapeutic
Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to...
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors
28 avr. 2021 16h01 HE
|
Morphic Therapeutic
WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to...
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting
12 avr. 2021 08h00 HE
|
Morphic Therapeutic
First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and...
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
02 mars 2021 20h25 HE
|
Morphic Therapeutic
WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...
Morphic Therapeutic Announces Proposed Public Offering
01 mars 2021 16h01 HE
|
Morphic Therapeutic
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
01 mars 2021 07h00 HE
|
Morphic Therapeutic
MORF-057 well tolerated in all dose cohorts MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 integrin at three highest dose levels; demonstrates ability to saturate α4β7 receptor ...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020
01 mars 2021 06h55 HE
|
Morphic Therapeutic
Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 AbbVie exercised license option to αvβ6 integrin inhibitor program for fibrotic diseases Expanded research and...
Morphic Therapeutic to Host Analyst and Investor Call on March 1, 2021
22 févr. 2021 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...